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The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study (1985–1993) recruited 29,133 Finnish
male cigarette smokers, ﬁnding that vitamin E supplementation had no overall effect on mortality. The authors of
this paper found that the effect of vitamin E on respiratory infections in ATBC Study participants was modiﬁed by
age, smoking, and dietary vitamin C intake; therefore, they examined whether the effect of vitamin E supplemen-
tation on mortality is modiﬁed by the same variables. During a median follow-up time of 6.1 years, 3,571 deaths
occurred. Age and dietary vitamin C intake had a second-order interaction with vitamin E supplementation of
50 mg/day. Among participants with a dietary vitamin C intake above the median of 90 mg/day, vitamin E increased
mortality among those aged 50–62 years by 19% (95% conﬁdence interval: 5, 35), whereas vitamin E decreased
mortality among those aged 66–69 years by 41% (95% CI:  56,  21). Vitamin E had no effect on participants who
had a dietary vitamin C intake below the median. Smoking quantity did not modify the effect of vitamin E. This study
provides strong evidence that the effect of vitamin E supplementation on mortality varies between different
population groups. Further study is needed to conﬁrm this heterogeneity.
aging; antioxidants; oxidative stress; population characteristics; randomized controlled trial; smoking; survival rate
Abbreviations: ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention; CI, conﬁdence interval; RR, risk ratio.
Taking vitamin E supplements is a common practice,
particularly among older people. In the United States, about
a quarter of adults aged 60 years or older take supplements
containing vitamin E (1). Such a common habit makes the
health effects of this practice an important public health
issue: does vitamin E supplementation improve health or
not?
The rationale behind taking the lipid-soluble antioxidant
vitamin E is to protect against oxidative stress, which con-
tributes to the aging processes and may affect longevity
(2, 3). However, 3 meta-analyses of randomized trials found
that vitamin E supplementation did not reduce mortality,
implying that vitamin E does not lead to universal systemic
beneﬁts against the processes that lead to chronic disease
(4–6).
Vitamin E is a major lipid-soluble antioxidant, whereas
vitamin C is a major water-soluble antioxidant. They inter-
act in vitro and in vivo (7–11). Smoking increases the
plasma a-tocopherol disappearance rate, which is normal-
ized by vitamin C supplementation (10). Thus, since smok-
ing seems to modify the interaction of these 2 antioxidants,
intake of vitamin C is particularly important when examin-
ing the effect of vitamin E on smokers.
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention
(ATBC) Study was a randomized, double-blind, placebo-
controlled trial that examined the effects of vitamin E and
b-carotene on lung cancer in male smokers (12, 13). Pre-
viously, we found signiﬁcant heterogeneity in the effects of
vitamin E supplementation in the ATBC Study; vitamin E
increased the risk of tuberculosis for heavy smokers with
high dietary vitamin C intake but had no effect on other
participants (14). The effect of vitamin E on common cold
and pneumonia risk was modiﬁed by age and smoking (11,
15–19).
In the ATBC Study, vitamin E supplementation had no
overall effect on mortality (12). In this study, we tested the
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min E supplementation on respiratory infections would also
modify the effect of vitamin E on mortality. We did not
presume that changes in the incidence of respiratory infec-
tions would signiﬁcantly affect overall mortality, but that
changes in respiratory infections may reﬂect nonspeciﬁc
systemic effects of vitamin E that might also affect
mortality.
MATERIALS AND METHODS
Participants
The design and methods of the ATBC Study examining
the effects of vitamin E (dl-a-tocopheryl acetate, 50 mg/day)
and b-carotene (20 mg/day) on the incidence of lung cancer
and other cancers have been described earlier (12, 13).
The ATBC Study is registered at the website www.
ClinicalTrials.gov under the identiﬁer NCT00342992.
In brief, male participants aged 50–69 years had to smoke
5 or more cigarettes per day at entry to be eligible, and those
enrolled in the trial (N ¼ 29,133) were randomized to 1 of 4
intervention arms and were administered placebo, vitamin
E, b-carotene, or vitamin E þ b-carotene; a 2 3 2 factorial
design was used. Compliance with supplementation was
high: some 90% of the participants took more than 90%
of their prescribed capsules during their active participation
in the trial; there were no differences in capsule consump-
tion among the intervention groups (13). Supplementation
increased the serum level of a-tocopherol by 50% compared
with baseline levels (12, 13). The intervention continued
until April 30, 1993. The trial was approved by the institu-
tional review boards, and all participants gave written in-
formed consent.
Baseline characteristics
Before randomization at baseline, the men completed
questionnaires on their medical and smoking histories and
general background characteristics, and their weight was
measured. A detailed dietary history questionnaire provided
data regarding vitamin C, vitamin E, fruit, vegetable, and
berry consumption (20, 21). The validity of the dietary his-
tory questionnaire was assessed by comparing it with the
food consumption records of 190 participants for 12 sepa-
rate 2-day periods distributed evenly over 6 months. Clas-
siﬁed by the dietary history questionnaire, 74%–76% of
participants categorized by food consumption records were
in the same vitamin C intake quintile or in the within-one-
quintile category (20). Dietary data were not available for
2,022 of the 29,133 participants.
Outcome and follow-up time
Deaths were identiﬁed by using the National Death Reg-
istry, as previously described (12). In the database we ana-
lyzed was one death additional to those in the 1994 report.
Follow-up time for each participant began from the day of
randomization and continued until death or the end of the
trial. The median follow-up time for the participants in the
present analysis was 6.1 years, and there was a total of
169,731 person-years of observation.
Statistical models
We estimated the effect of vitamin E supplementation on
mortality through proportional hazards regression models.
We calculated the risk ratio and the 95% conﬁdence interval
of the risk ratio by using the PROC PHREG procedure in
SAS software (release 8.2; SAS Institute, Inc., Cary, North
Carolina). The 2 3 2 factorial design of the trial permitted
assessment of the effect of vitamin E independent of
b-carotene after conﬁrming no statistical interaction be-
tween the agents. Thus, we compared the trial participants
administered vitamin E with those not receiving vitamin E
(no-vitamin-E participants). We did not analyze the effects
of b-carotene in this study. Regarding supplementation, we
carried out the analyses following the intention-to-treat
principle. Because deaths were identiﬁed in the National
Death Registry, which registers all deaths occurring in
Finland, loss-to-follow-up is insigniﬁcant.
To test the statistical signiﬁcance of interaction between
vitamin E supplementation and potential modifying factors,
weﬁrstaddedthesupplementationandmodifyingfactortothe
regressionmodel.Thestatisticalsigniﬁcanceoftheinteraction
was thereafter calculated from the change in  2 3 log(likeli-
hood)whentheinteractiontermofvitaminEsupplementation
and the modifying factor was added to the model.
In our subgroup analyses, we split dietary vitamin E and C
levels,and the residual offruit,vegetable,and berryconsump-
tion, at rounded levels close to the medians. Dietary vitamin C
was also used as a continuous variable because interaction
with a continuous variable refutes the possibility that dichot-
omizing dietary vitamin C intake might cause a spurious in-
teraction; to decrease the skewness of the distribution, the
statistical model included the logarithm of dietary vitamin C
intake.
Nelson-Aalen cumulative hazard functions were con-
structed by using the STATA sts program (release 9.1; Stata
Corporation, College Station, Texas). Two-tailed P values
were used.
Examination of the speciﬁcity of effect modiﬁcation by
vitamin C
The major sources of vitamin C in the diet of study par-
ticipants were fruit, vegetables, and berries, on average 58%
of dietary vitamin C originating from these foods. Total in-
take of fruit, vegetables, and berries was strongly correlated
with the calculated vitamin C intake (r ¼ 0.88). Thus, it is
possible that an association with dietary vitamin C is a sta-
tistical artifact reﬂecting other substances in these foods or
the lifestyle related to eating these foods. To examine the
possible role of dietary compounds other than vitamin C in
these foods, we calculated the residual of fruit, vegetables,
and berries intake by using linear regression to model fruit,
vegetables, and berries as a function of dietary vitamin C, as
previously (22). As designed, the residual of fruit, vegeta-
bles, and berries intake has no correlation with dietary vita-
min C. We assumed that any other putative compound that
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correlationwithvitaminCand,therefore,thatvariationinthe
other compound remains as variation in the residual of fruit,
vegetables, and berries intake, which was split at 0 g/day,
close to the median. High residual of fruit, vegetables, and
berries intake (above zero) indicates that the participant with
a given vitamin C level consumes more than the average
quantity of fruit, vegetables, and berries, whereas low resid-
ual of fruit, vegetables, and berries intake (below zero) in-
dicates less-than-average intake of these food classes.
RESULTS
During the 169,731 person-years of follow-up of the
ATBC Study participants, 3,571 deaths occurred, equivalent
to 21.0 deaths per 1,000 person-years. The deaths were
equally divided between the vitamin E and no-vitamin-E
groups: 1,801 vs. 1,770, corresponding to a risk ratio of
1.02 (95% conﬁdence interval (CI): 0.95, 1.09).
Dietary vitamin C intake did not modify the effect of
vitamin E supplementation. For participants with a vitamin
C intake of less than 90 mg/day, the effect of vitamin E on
mortality was a risk ratio of 1.00 (95% CI: 0.92, 1.11); for
those with a higher vitamin C intake, the effect was a risk
ratio of 1.04 (95% CI: 0.94, 1.16). Age did not modify the
effect of vitamin E (P ¼ 0.06; interaction betweenvitamin E
and age as a continuous variable).
We found that vitamin E supplementation had a second-
order interaction with dietary vitamin C and age (Table 1).
Vitamin E did not affect mortality for participants with low
vitamin C intake. However, for participants with high dietary
vitamin C intake, the effect of vitamin E depended on age, so
that it increased mortality in the young (aged <63 years)
participants by 19% but reduced mortality in the old (aged
 66 years) participants by 41% (Table 1, Figures 1 and 2).
Division of participants into the age categories shown in
Table 1 was based on the inspection of data, but the ﬁndings
were not sensitive to the cutpoints of age. For young partic-
ipants with high vitamin C intake, the point estimate of the
vitamin E effect was very similar in narrower age catego-
ries: risk ratio ¼ 1.17 (95% CI: 0.93, 1.48; 297 deaths), risk
ratio ¼ 1.25 (95% CI: 1.02, 1.53; 371 deaths), and risk
ratio ¼ 1.13 (95% CI: 0.92, 1.40; 353 deaths) in the groups
aged 50–54, 55–58, and 59–62 years, respectively, which
justiﬁed combining these age groups. In participants aged
66–69 years with high dietary vitamin C intake, vitamin E
had the same effect in 2-year categories: risk ratio ¼ 0.58
(95% CI: 0.39, 0.86; 113 deaths) and risk ratio ¼ 0.58 (95%
CI: 0.37, 0.91; 82 deaths) in the groups aged 66–67 and
68–69 years, respectively.
There seemed to be an approximately 3-year lag period
before vitamin E started to increase the mortality of partic-
ipantsaged50–62yearswithhighvitaminCintake(Figure1).
During the ﬁrst 3 years, vitamin E had no effect on mor-
tality, but thereafter it increased mortality by 38%. Inclu-
sion of the lag period in the regression model led to
signiﬁcant improvement in the model. The survival curves
for participants aged 66–69 years suggested a 2-year lag
period (Figure 2).
The main food sources of vitamin C are fruit, vegetables,
and berries. Thus, modiﬁcation of the vitamin E effect by
dietary vitamin C might be explained by high levels of other
substances in these foods. Residual fruit, vegetables, and
berry intake (refer to the Materials and Methods section)
did not modify the effect of vitamin E in participants aged
50–62 years (Table 2), indicating that other substances in
these foods do not explain the effect modiﬁcation by vitamin C.
The vitamin E effect was modiﬁed by vitamin C as a con-
tinuous variable, indicating that the cutpoint for dichotomi-
zation was not crucial to the ﬁnding. Dietary vitamin E
intake and b-carotene supplementation did not modify the
effect of vitamin E supplementation. In the participants aged
Table 1. Effect of Vitamin E Supplementation on Mortality by Age
and Dietary Vitamin C Intake, Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study, 1985–1993
Age at Baseline
Vitamin C Test for
Vitamin C
Interaction
(P Value)
<90 mg/day
(n 5 13,567)
a
‡90 mg/day
(n 5 13,544)
a
50–62 years
(n ¼ 22,413)
Risk ratio
b 1.00 1.19 0.048
95% conﬁdence
interval
0.90, 1.13 1.05, 1.35
Deaths
c 614/616 552/469
63–65 years
(n ¼ 2,761)
Risk ratio
b 0.95 0.89 0.7
95% conﬁdence
interval
0.75, 1.20 0.68, 1.17
Deaths
c 142/139 106/110
66–69 years
(n ¼ 1,937)
Risk ratio
b 1.07 0.59 0.002
95% conﬁdence
interval
0.84, 1.36 0.44, 0.79
Deaths
c 139/137 71/124
Test for interaction;
age as a continuous
variable (P value)
d
0.4 0.0003
a Information on dietary vitamin C intake was missing for 2,022
participants, with 177 deaths of vitamin-E and 175 deaths of no-
vitamin-E participants.
b Proportional hazards regression model comparing participants
who received vitamin E with those who did not.
c Number of deaths of vitamin-E participants/number of deaths of
no-vitamin-E participants.
d The second-order interactionterm betweenvitaminE supplemen-
tation, dietary vitamin C, and age improved the regression model by
v
2(1 df) ¼ 10.1, P ¼ 0.0015. The uniformity of the vitamin E effect
was also tested by adding a dummy variable for vitamin E effect in
5 groups of the table, allowing each of the 6 groups its own vitamin E
supplementation effect. The regression model was improved by
v
2(5 df) ¼ 22.2, P ¼ 0.0005 compared with the model with a uniform
vitamin E effect. Adding the vitamin E effect to only those groups aged
50–62 and 66–69 years with high vitamin C intake led to similar im-
provement in the regression model, by v
2(2 df) ¼ 21.0 compared with
the model with a uniform vitamin E effect.
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dietary vitamin E intake; and b-carotene supplementation
did not modify the effect of vitamin E (Table 3).
Smokinghadamarginallysigniﬁcantmodiﬁcationeffecton
the participants aged 66–69 years with high vitamin C intake
(P ¼ 0.051). The decrease in mortality with vitamin E
supplementation was more evident for those who smoked
less than a pack of cigarettes per day (risk ratio (RR) ¼
0.44, 95% CI: 0.28, 0.68; 89 deaths) compared with
a pack or more (RR ¼ 0.78, 95% CI: 0.53, 1.15; 106
deaths). For the participants aged 50–62 years with high
vitamin C intake, the effect was more apparent for those
who smoked a pack of cigarettes or more per day (RR ¼
1.22, 95% CI: 1.05, 1.42; 689 deaths) than for those who
smoked less (RR ¼ 1.12, 95% CI: 0.90, 1.39; 332 deaths),
but the conﬁdence intervals overlapped broadly and the
difference was not statistically signiﬁcant (P ¼ 0.5 in
heterogeneity test).
Of the participants aged 66–69 years with high vitamin C
intake, 16.7% of the vitamin-E participants died during
follow-up, whereas 27.7% of the no-vitamin-E participants
died. Thus, based on the baseline cohort, the number needed
to treat to prevent one death during follow-up was 9.1 in this
subgroup. On the other hand, the cumulative hazard esti-
mates over the 8-year follow-up (Figure 2) indicate mor-
tality of 28% in the vitamin-E group and 49% in the
no-vitamin-E group, corresponding to the number needed
to treat of 4.8 over an 8-year supplementation period.
DISCUSSION
Vitamin E supplementation had no overall effect on mor-
tality among the ATBC Study participants, yet we found
strong evidence of heterogeneity between subgroups.
Vitamin E increased, decreased, or had no effect on mortal-
ity depending on age and vitamin C intake. The numerical
estimates calculated for the subgroups are less essential than
the strong evidence of heterogeneity. When the effect of
vitamin E depends on the characteristics of people, it seems
obvious that the estimates of intervention effect obtained
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Figure 1. Effect of vitamin E supplementation on mortality among
participants aged 50–62 years with a dietary vitamin C intake of
>90 mg/day (n ¼ 11,448 with 1,021 deaths), Alpha-Tocopherol,
Beta-Carotene Cancer Prevention Study, 1985–1993. Nelson-Aalen
cumulative hazard functions for the vitamin-E and no-vitamin-E
groups are shown. Each step indicates 1 death. For the difference
between the 2 groups, log-rank-test P ¼ 0.006. The number of par-
ticipants with follow-up time of  7 years was 2,316; the curves are cut
at 7.8 years because the number of participants declined abruptly
thereafter. The possibility of a lag period was examined by adding
a different risk ratio term for vitamin E effect starting at variable time
points. The best improvement in the regression model was achieved
by adding the second vitamin E effect starting at 3.3 person-years,
which improved the regression model by v
2(1 df) ¼ 7.1, P ¼ 0.007.
This model gives risk ratios of 0.99 (95% conﬁdence interval: 0.82,
1.19) during the ﬁrst 3.3 years and 1.38 (95% conﬁdence interval:
1.17, 1.63) thereafter.
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Figure 2. Effect of vitamin E supplementation on mortality among
participants aged 66–69 years with a dietary vitamin C intake of >90
mg/day (n ¼ 872 with 195 deaths), Alpha-Tocopherol, Beta-Carotene
Cancer Prevention Study, 1985–1993. Nelson-Aalen cumulative haz-
ard functions for the vitamin-E and no-vitamin-E groups are shown.
Each step indicates 1 death. For the difference between the 2 groups,
log-rank-test P ¼ 0.0003. The number of participants with follow-up
time of  7 years was 128; the curves are cut at 7.8 years because the
number of participants declined abruptly thereafter. The possibility of
a lag period was examined by adding 2 different risk ratio terms for
vitamin E effect starting at variable time points because the 2 curves
diverge at the initiation of supplementation and at about 2 years. The
best improvement in the regression model was achieved by adding
the second vitamin E effect starting at 0.3 person-years and the third
risk ratiostartingfrom1.9 years,whichimprovedtheregressionmodel
by v
2(2 df) ¼ 5.2, P ¼ 0.073. This model gives risk ratios of 0.15
(95% conﬁdence interval: 0.02, 1.2) during the ﬁrst 0.3 years, 1.04
(95% conﬁdence interval: 0.53, 2.04) during the period 0.3–1.9 years,
and 0.54 (95% conﬁdence interval: 0.39, 0.76) thereafter. During the
ﬁrst 0.3 years of follow-up, there were 5 deaths in the b-carotene arm,
2 deaths in the placebo arm, 1 death in the vitamin E arm, and no
deaths in the vitamin E þ b-carotene arm.
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population groups.
Although we divided the participants into several sub-
groups, the multiple comparison problem did not seem to be
a concerninourstudy.First,thesubgroupheterogeneityinthe
6 groups deﬁned by age and dietary vitamin C intake was
signiﬁcant even when we allowed each of the 6 subgroups to
have its own vitamin E effect (Table 1). Second, our current
subgroup analyses tested our earlier subgroup ﬁndings for res-
piratory infection outcomes in the ATBC Study (11, 14–19).
Our ﬁndings have several important implications. Sub-
group analysis has been discouraged because it can lead to
false-positive ﬁndings due to the multiple comparison prob-
lem (23–25). It has even been argued that ‘‘believing that
a treatment effect exists in one stratum of patients, even
though no overall signiﬁcant treatment effect exists, is
a common error’’ (24, p. 15). Furthermore, large trials are
set up after years of deliberation by experts, and it is as-
sumed that all relevant knowledge is therefore incorporated
into the study plans (25). However, biology is complex, and
it seems unlikely that all important biologic knowledge
could ever be taken into account properly when setting up
a pragmatic controlled trial. A single estimate of treatment
effect calculated for a large population can be misleading if
it is thought to be valid for all participants, as shown in our
work. The overall estimate for all ATBC Study participants,
risk ratio ¼ 1.02, is inconsistent with our subgroup ﬁndings
for nearly half of all participants, that is, the young and old
with high dietary vitamin C intake.
Our current study and earlier subgroup analyses of the
ATBC Study suggest that subgroup analyses of large trial
databases should be encouraged even if there is no overall
effect in the study population, keeping in mind the possibil-
ity of spurious ﬁndings from multiple testing. Given the
long-term commitment of participants and the resources
invested, it might even be considered a moral imperative
to analyze the large trial databases as extensively as possible
rather than simply to calculate an overall effect. Evidently,
subgroup ﬁndings should be considered cautiously, and the
interpretation of P values must be related to the number of
subgroup analyses being carried out. Nevertheless, our sub-
group ﬁndings in the ATBC Study point out the need for
further research on vitamin E, whereas the overall estimate
of effect suggests that no further studies would have been
worthwhile. We concur with Feinstein’s concern (26) that
anti-subgroup doctrines have become so entrenched that
they often hamper investigation of socially and biologically
sound subgroups with public health relevance.
Table 2. Speciﬁcity of Vitamin C in Modifying the Effect of Vitamin E Supplementation on the
Mortality of Participants Aged 50–62 Years, Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study, 1985–1993
Subgroup No. of
Participants
Vitamin E No Vitamin E
Risk
Ratio
a
95%
Conﬁdence
Interval
Test of
Interaction
(P Value)
No. of
Deaths Rate
b No. of
Deaths Rate
b
All 24,000 1,292 18.4 1,202 17.0 1.08 1.00, 1.17
Dietary vitamin C
c
<90 mg/day 10,965 614 19.2 616 19.1 1.00 0.90, 1.13 0.048
d
 90 mg/day 11,448 552 16.3 469 13.7 1.19 1.05, 1.35
Residual of fruit,
vegetables,
and berries
e
<0 g/day 11,839 638 18.5 575 16.5 1.11 1.00, 1.25 0.5
 0 g/day 10,574 528 16.9 510 16.1 1.05 0.93, 1.19
Dietary vitamin E
c
<10 mg/day 9,295 516 19.1 499 18.2 1.05 0.92, 1.19 0.5
 10 mg/day 13,118 650 16.8 586 15.0 1.11 1.00, 1.25
b-Carotene
No 12,041 617 17.5 567 15.9 1.10 0.98, 1.23 0.7
Yes 11,959 675 19.3 635 18.1 1.06 0.95, 1.19
a Proportional hazards regression model comparing participants who received vitamin E with
those who did not.
b Number of deaths per 1,000 person-years.
c Information on dietary vitamins C and E intake was missing for 1,587 participants, with 126
deaths of vitamin-E and 117 deaths of no-vitamin-E participants.
d Dietary vitamin C as a continuous variable: test for vitamin E interaction, P ¼ 0.011.
e Difference between an individual’s intake and the mean intake with a given dietary vitamin C
intake; refer to the Materials and Methods section of the text. Information on fruit, vegetables, and
berries intake was missing for 1,587 participants, with 126 deaths of vitamin-E and 117 deaths of
no-vitamin-E participants.
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vitamin E supplementation on mortality (4–6). Combining
several large trials leads to estimates with narrow conﬁdence
intervals; however, pooling is based on the assumption of the
same universal effect in all populations of the combined
studies. Our strong evidence of heterogeneity in the ATBC
Study refutes the assumption of a uniform effect and casts
doubt on the validity of the pooled estimates of the meta-
analyses. Although the pooled estimates reject the proposal
thatvitaminEsupplementationwouldbebeneﬁcialforwide-
ranging population groups, our study suggests that important
subgroupsbeingharmedorbeneﬁtingfromvitaminEmaybe
hidden in the misleadingly narrow conﬁdence intervals.
The recently published Physicians’ Health Study II found
no overall effect of vitamin E and C supplementation on
mortality (27). However, the lack of average effect does
not conﬂict with our ﬁndings of heterogeneity because vi-
tamin E had no overall effect in the ATBC Study either. The
number of deaths in the ATBC Study (n ¼ 3,571) was twice
that in the Physicians’ Health Study II (n ¼ 1,661); conse-
quently, there is more statistical power to analyze potential
subgroup differences in the ATBC Study. Furthermore,
ATBC Study participants were recruited from the general
population, so there is greater potential for analyzing het-
erogeneity compared with the Physicians’ Health Study II
focused on a single upper-class profession.
OurstrongestﬁndingsconcernvitaminEsupplementation
because the division of participants into vitamin-E and no-
vitamin-Egroupswasrandom.Theevidenceofheterogeneity
of thevitamin Eeffectisstrongirrespectiveofthespeciﬁcity
of vitamin C as the modiﬁer. Nevertheless, by using the re-
sidual of fruit, vegetables, and berries, which has no corre-
lation with dietary vitamin C, we were able to show that
modiﬁcation ofthevitaminEeffect isnot explainedby other
substances in these foods, suggesting that vitamin C is the
speciﬁcsubstanceexplainingthe modiﬁcation.Furthermore,
thesubgroupdivisionsinourcurrentstudywerebasedonthe
effects of vitamin E on respiratory infections, and vitamin C
has also affected respiratory infections in certain controlled
trials, showing that its physiologic effects are not limited to
preventing scurvy (28, 29). Finally, the interaction between
vitamins E and C is well established (7–11). These argu-
ments support the possibility that vitamin C speciﬁcally
causes the modiﬁcation of the vitamin E effect, although our
vitamin C intake levels were based on observational data.
All ATBC Study participants were smokers, and no direct
conclusions can be drawn for nonsmokers. The beneﬁt of
vitamin E supplementation on respiratory infections was
Table 3. Speciﬁcity of Vitamin C in Modifying the Effect of Vitamin E Supplementation on the
Mortality of Participants Aged 66–69 Years, Alpha-Tocopherol, Beta-Carotene Cancer
Prevention Study, 1985–1993
Subgroup No. of
Participants
Vitamin E No Vitamin E
Risk
Ratio
a
95%
Conﬁdence
Interval
Test of
Interaction
(P Value)
No. of
Deaths Rate
b No. of
Deaths Rate
b
All 2,140 237 41.6 291 48.6 0.87 0.73, 1.03
Dietary vitamin C
c
<90 mg/day 1,065 139 49.6 137 46.4 1.07 0.84, 1.36 0.002
d
 90 mg/day 872 71 29.6 124 50.8 0.59 0.44, 0.79
Residual of fruit,
vegetables,
and berries
e
<0 g/day 992 111 41.3 127 47.9 0.88 0.68, 1.13 0.7
 0 g/day 945 99 39.3 134 48.9 0.81 0.62, 1.05
Dietary vitamin E
c
<10 mg/day 1,057 123 43.8 144 49.7 0.89 0.69, 1.13 0.5
 10 mg/day 880 87 36.4 117 46.9 0.78 0.59, 1.03
b-Carotene
No 1,070 122 41.5 143 49.6 0.85 0.66, 1.08 0.8
Yes 1,070 115 41.7 148 47.6 0.89 0.69, 1.13
a Proportional hazards regression model comparing participants who received vitamin E with
those who did not.
b Number of deaths per 1,000 person-years.
c Information on dietary vitamins C and E intake was missing for 203 participants, with 27
deaths of vitamin-E and 30 deaths of no-vitamin-E participants.
d Dietary vitamin C as a continuous variable: test for vitamin E interaction, P ¼ 0.002.
e Difference between an individual’s intake and the mean intake with a given dietary vitamin C
intake; refer to the Materials and Methods section of the text. Information on fruit, vegetables, and
berries intake was missing for 203 participants, with 27 deaths of vitamin-E and 30 deaths of no-
vitamin-E participants.
Vitamin E Supplementation and Heterogeneity in Mortality 951
Am J Epidemiol 2009;169:946–953previously more evident in ATBC Study participants who
smoked less, and the harm was more apparent in those who
smoked more (14, 15, 18, 19). We saw similar trends in the
effect of vitamin E on mortality, but the modiﬁcation of the
vitamin E effect caused by smoking quantity was not statis-
ticallysigniﬁcant.Nevertheless,thegreaterreductioninmor-
tality among old participants with high vitamin C intakewho
smoked less suggests that vitamin E supplementation might
affect mortality among older male nonsmokers as well.
Since vitamin E is a fat-soluble substance and it may take
months before tissue levels are substantially elevated (30,
31), short trials may be uninformative. In the current study,
there seemed to be 2- and 3-year lag periods before vitamin
E started to decrease or increase mortality (Figures 1 and 2).
These lag periods are consistent with a delay in the effects of
the fat-soluble vitamin. Nevertheless, the maximum of
8 years of follow-up in the ATBC Study was long enough
to observethat vitamin E supplementation does have effects.
On the other hand, the risk of tuberculosis increased signif-
icantly within a year of supplementation being initiated (14)
and the risk of pneumonia in participants who exercised in
their leisure time decreased without a lag (16), so not all
effects of vitamin E are delayed.
It has been suggested that the vitamin E doses in the ran-
domizedtrials were too low to show any effect (32), andhigh
doses in some trials increased mortality (5). Given our ob-
servations that 50 mg/day of vitamin E caused signiﬁcant
increase and decrease in mortality in the ATBC Study pop-
ulation, depending on the characteristics of participants, no
justiﬁcation exists for claiming that the vitamin E doses in
randomized trials have been too low. Our study also suggests
that it may be primarily subject characteristics and not dose
of vitamin E that determines whethervitamin E causes harm.
Many people take vitamin E supplements because they
believe that the vitamin protects them against oxidative
stress, which has a role in the aging processes (2, 3). Our
ﬁndings among the older ATBC Study participants are con-
sistent with the concept that the antioxidant vitamins C and
E can counteract oxidative stress processes in old people
under some conditions. Assuming that the beneﬁt of vitamin
E supplementation in old people is conditional on a high
intake of vitamin C, it seems possible that old people with
low dietary vitamin C might beneﬁt from a combination of
the 2. Therefore, the most informative type of further study
would be a factorial design with vitamins E and C on old
people with low dietary vitamin C intake.
Finally, the US nutritional recommendations and a recent
review consider that vitamin E is safe in doses up to 1,000
mg/day (33, 34). Our ﬁnding that 50 mg/day of vitamin E
signiﬁcantly increased mortality among half of the male
smokers in the ATBC Study aged 50–62 years contradicts
theuniversalsafetyof1,000mg/dayofvitaminE.Previously,
we found that 50 mg/day of vitamin E signiﬁcantly increased
the risk of the common cold, pneumonia, and tuberculosis in
subgroupsoftheATBCStudy, alsoindicatingthat sucha low
dose can cause harmful effects in some people (14, 18, 19).
In conclusion, our subgroup analyses of the ATBC Study
cohort support the conclusions of meta-analysis of con-
trolled trials (4–6), in that vitamin E supplementation seems
ineffective or harmful for middle-aged male smokers. Evi-
dently, in people younger than age 65 years, taking vitamin
E supplements should be strongly discouraged until clear
evidence emerges that some population groups of younger
or middle-aged people beneﬁt. On the other hand, our study
indicates that vitamin E supplementation may lead to ben-
eﬁcial effects in some subgroups of old people, and this
possibility should be investigated by using a factorial design
with vitamin C supplementation. Finally, the substantial de-
crease in mortality with vitamin E supplementation among
the older participants with high dietary vitamin C intake
raises the question of whether the decrease in overall mor-
tality is attributable to a single cause of death or a few
causes, or whether it suggests a general decrease in frailty
reﬂected in lessened mortality from diverse causes.
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